Cutaneous Innate Immune Sensing of Toll-like Receptor 2-6 Ligands Suppresses T Cell Immunity by Inducing Myeloid-Derived Suppressor Cells  by Skabytska, Yuliya et al.
Immunity
ArticleCutaneous Innate Immune Sensing of Toll-like
Receptor 2-6 Ligands Suppresses T Cell Immunity
by Inducing Myeloid-Derived Suppressor Cells
Yuliya Skabytska,1 Florian Wo¨lbing,1 Claudia Gu¨nther,2 Martin Ko¨berle,1,3 Susanne Kaesler,1 Ko-Ming Chen,1
Emmanuella Guenova,1,4 Doruk Demircioglu,5 Wolfgang E. Kempf,1,3 Thomas Volz,1,3 Hans-Georg Rammensee,6
Martin Schaller,1 Martin Ro¨cken,1 Friedrich Go¨tz,5 and Tilo Biedermann1,3,*
1Department of Dermatology, Eberhard Karls University, Liebermeisterstrasse 25, 72076 Tu¨bingen, Germany
2Department of Dermatology, Technical University Dresden, Mommsenstrasse 11, 01069 Dresden, Germany
3Department of Dermatology and Allergy, Technische Universita¨t Mu¨nchen, Biedersteinerstrasse 29, 80802 Munich, Germany
4Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, CH-8091 Zurich, Switzerland
5Department of Microbial Genetics, Eberhard Karls University, Waldha¨user Straße 70/8, 72076 Tu¨bingen, Germany
6Department of Immunology, Institute of Cell Biology, and German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)
Partner Site Tu¨bingen, Eberhard Karls University, Auf der Morgenstelle 15, 72076 Tu¨bingen, Germany
*Correspondence: tilo.biedermann@tum.de
http://dx.doi.org/10.1016/j.immuni.2014.10.009SUMMARY
Skin is constantly exposed to bacteria and antigens,
and cutaneous innate immune sensing orchestrates
adaptive immune responses. In its absence, skin
pathogens can expand, entering deeper tissues
and leading to life-threatening infectious diseases.
To characterize skin-driven immunity better, we
applied living bacteria, defined lipopeptides, and
antigens cutaneously. We found suppression of im-
mune responses due to cutaneous infection with
Gram-positive S. aureus, which was based on bacte-
rial lipopeptides. Skin exposure to Toll-like receptor
(TLR)2-6-binding lipopeptides, but not TLR2-1-
binding lipopeptides, potently suppressed immune
responses through induction of Gr1+CD11b+
myeloid-derived suppressor cells (MDSCs). Investi-
gating human atopic dermatitis, in which Gram-pos-
itive bacteria accumulate, we detected high MDSC
amounts in blood and skin. TLR2 activation in skin
resident cells triggered interleukin-6 (IL-6), which
induced suppressive MDSCs, which are then re-
cruited to the skin suppressing T cell-mediated recall
responses such as dermatitis. Thus, cutaneous bac-
teria can negatively regulate skin-driven immune re-
sponses by inducing MDSCs via TLR2-6 activation.
INTRODUCTION
The skin is the largest organ at the interface between the environ-
ment and the host. The skin plays a major protective role not
only as physical barrier but also as the site of first recognition
of microbes and orchestrates consecutive immune responses
(Naik et al., 2012; Swamy et al., 2010; Volz et al., 2012).
Staphylococcus aureus (S. aureus) is one of the most potent
skin pathogens and is found to colonize skin of about 30%–762 Immunity 41, 762–775, November 20, 2014 ª2014 Elsevier Inc.50% of healthy adults, among them 10%–20% persistently
(Lowy, 1998). Coming from the skin, S. aureus can infect any tis-
sue of the body and cause life-threatening diseases, particularly
because of the widespread occurrence of antibiotic-resistant
strains, known as methicillin-resistant Staphylococcus aureus
(MRSA) (Saeed et al., 2014). In atopic dermatitis (AD) patients,
there is an approximately 200-fold increase of S. aureus coloni-
zation with more than 90% of AD patients displaying S. aureus in
comparison to the healthy skin (Leung and Bieber, 2003).
Microbes are first sensed by the innate immune system
through pattern-recognition receptors (PRRs), which recognize
microbe-associated molecular patterns (MAMPs) (Kawai and
Akira, 2010). Both epithelial cells and resident innate immune
cells in the skin express PRRs (Kupper and Fuhlbrigge, 2004;
Lai and Gallo, 2008). Among PRRs, Toll-like receptors (TLRs)
are a well-characterized family with distinct recognition profiles
(Kawai and Akira, 2010). TLR2 has emerged as a dominant re-
ceptor for Gram-positive bacteria, especially S. aureus (Bieder-
mann, 2006; Lai and Gallo, 2008; Mempel et al., 2003). Among
TLR2 ligands, lipoproteins seem to be especially important
because the lipoprotein diacylglyceryl transferase (lgt) deletion
mutant of S. aureus induces much less proinflammatory cyto-
kines in human cell lines (Stoll et al., 2005) and less TLR2-
MyD88 adaptor protein-mediated inflammation in a mouse
model of systemic infection (Schmaler et al., 2009). It is now es-
tablished that there are different classes of lipopeptides that all
bind TLR2 (Mu¨ller et al., 2010; Schmaler et al., 2009). However,
how these TLR2 ligands differ in regard to functional conse-
quences has not been thoroughly investigated. TLR2 is known
to form heterodimers with TLR1 and TLR6 to interact with this
broad spectrum of ligands (Kang et al., 2009). TLR1 is required
as a coreceptor for recognition of triacylated lipopeptides,
such as Pam3Cys (Buwitt-Beckmann et al., 2006; Jin et al.,
2007), while diacylated lipopeptides, such as FSL-1 or
Pam2Cys, interact with TLR2-TLR6 heterodimers (Mae et al.,
2007; Mu¨hlradt et al., 1997). Functional properties of S. aureus
lipopeptides in respect to TLR2 heterodimers have been investi-
gated in several cell types (Buwitt-Beckmann et al., 2006; Hajjar
et al., 2001), but evidence demonstrating specific functional
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is lacking.
Sustained activation of TLRs causes persistent production of
proinflammatory cytokines, such as tumor necrosis factor
(TNF) or interleukin-6 (IL-6), leading to tissue damage (Kawai
and Akira, 2010; Kupper and Fuhlbrigge, 2004; Lai and Gallo,
2008). Consequently, to reconstitute the integrity of the surface
organ, mechanisms to limit cutaneous inflammation must be
effective (Lai et al., 2009). In recent years, Gr1+CD11b+
myeloid-derived suppressor cells (MDSCs) have been identified
as one cell population responsible for modulating immune re-
sponses (Bronte, 2009; Gabrilovich and Nagaraj, 2009; Os-
trand-Rosenberg and Sinha, 2009). The most characteristic
functional property of MDSCs is to suppress T cell responses
(Gabrilovich et al., 2001; Kusmartsev et al., 2000). In the context
of inflammation the precise function of MDSCs and the mecha-
nisms of MDSC induction are not well-understood; but in a
sepsis model with Gram-negative bacteria their induction has
been shown to depend on TLR4-MyD88 activation (Delano
et al., 2007), and in tumor models, different innate cytokines,
such as IL-6, induce MDSC accumulation (Bunt et al., 2007;
Chalmin et al., 2010). However, the suppression of IL-6 also
increases susceptibility to bacterial and fungal infections, indi-
cating pleiotropic effects of IL-6 (Hoetzenecker et al., 2012).
In this study, we have identified a pathway of immune regula-
tion that operates in the skin. We mimicked intense cutaneous
contact to bacteria in different in vivo mouse models by using
living bacteria and lipopeptides. We investigated AD as a model
for massive cutaneous immune sensing of Gram-positive bacte-
ria in humans. We found that cutaneous infection with S. aureus
caused immune suppression. The exposure to TLR2-6 ligands
was sufficient to cause an almost complete reduction of consec-
utive cutaneous recall responses. This skin exposure induced
accumulation of MDSCs, allowing MDSC recruitment to the
skin, and suppression of T cell-mediated recall responses. Sig-
nals through TLR2 on skin-resident cells, but not on recruited
hematopoietic cells, as well as cutaneous IL-6 induction, were
necessary and sufficient for the expansion of MDSCs and
consecutive immune suppression. These data demonstrate
that cutaneous recognition of TLR2-6 ligands orchestrates a
unique pathway of cutaneous immune modulation mediated
by MDSCs, indicating a yet unknown level of immune
counterregulation.
RESULTS
Cutaneous Staphylococcus aureus Induces
Immune Suppression
We aimed to characterize the consequences of intense cuta-
neous innate immune sensing as in the case of colonization or
infection with Gram-positive bacteria. We established a mouse
model of epicutaneous colonization with pathologically relevant
S. aureus (Wanke et al., 2013). Mimicking S. aureus skin infection
by applying living S. aureus bacteria onto the skin with disrupted
skin barrier, we found a distribution of the bacteria not only in the
skin but also in the internal organs (spleen and kidney) (Fig-
ure 1A), indicating the importance of the skin as an effective
defense immune organwith the potential to impact the whole im-
mune system. To investigate how bacterial infection influencesIconsecutive immune responses, we combined this model of
bacterial colonization and the murine T cell-mediated contact
hypersensitivity (CHS) to FITC, in which bacteria were applied
epicutaneously during FITC re-exposure of FITC-sensitized
mice (see protocol in Figure S1A available online). The applica-
tion of FITC onto the ear led to FITC-specific dermatitis as deter-
mined by ear swelling, which corresponded to the strength of the
FITC-specific immune response. The cutaneous application of
S. aureus 7 days previous to the FITC challenge did not enhance,
but significantly reduced ear swelling and immune cell infiltration
(Figures 1B and 1C). This immune suppression was completely
dependent on immune sensing of bacterial lipoproteins, as lipo-
protein-deficient S. aureusmutant (Dlgt) (Stoll et al., 2005) failed
to induce immune suppression. Injecting S. aureus into the sub-
epithelial dermis (intracutaneous route) also induced consecu-
tive immune suppression, which, however, tended to be weaker
compared to effects of S. aureus application onto the epithelium
(Figure S1B). To identify underlying mechanisms of S. aureus-
induced cutaneous immune suppression, we analyzed skin-
draining lymph nodes. Only exposure to wild-type (WT)
S. aureus bacteria and not the lipoprotein-deficient Dlgt S.
aureus reduced ex vivo FITC-specific T cell proliferation (Fig-
ure 1D). In the spleen, CD4+ and CD8+ T cells were also reduced
in mice cutaneously exposed to WT S. aureus, but not in mice
exposed to lipoprotein-deficient Dlgt S. aureus (Figure 1E).
Only in mice displaying suppressed T cells we detected a
strong increase of Gr1+CD11b+ so-called myeloid-derived sup-
pressor cells (Figure 1E). In contrast to this, accumulation of
Gr1+CD11b+ was not detected in the liver (Figure S1D). At day
3 after FITC challenge, MDSCs were also slightly increased in
draining lymph nodes due to cutaneous WT S. aureus infection,
corresponding to the decrease of proliferating Ki67+ T cells (Fig-
ure S1E). Further experiments investigating other suppressive
cell populations showed no alterations in the number of regula-
tory T (Treg) cells and IL-10-producing cells (Figure S1F); the
numbers of Langerhans cells (LCs, defined as CD11cloCD205hi)
and CD11c+MHC-II+ cells were also unchanged, and dermal
dendritic cells (dDCs, defined as CD11chiCD205lo) were slightly
increased (Figure S1E). These data indicate thatMDSCs function
independently of Treg cells and do not inhibit migration of DCs
into lymph nodes.
In order to further emphasize the functional and clinical rele-
vance of these findings, we investigated atopic dermatitis (AD)
patients. AD is a perfectly suited model disease for investiga-
tions on immune consequences of skin exposure to bacteria,
because AD is an inflammatory skin disease that is nearly always
covered with and triggered by Staphylococci. In humans,
MDSCs are typically described as CD11b+CD33+HLA-DR
CD14 cells (Gabrilovich and Nagaraj, 2009). We observed a
significant increase of MDSCs in the peripheral blood mononu-
clear cells (PBMCs) of AD patients (Figure 1F). The upregulation
of human MDSCs was especially consistent in patients, in which
severe AD was complicated by eczema herpeticum, which is a
severe cutaneous viral infection resulting from immune suppres-
sion (Figure 1F, red squares) (Beck et al., 2009; Wollenberg
et al., 2003), suggesting suppressive properties of MDSCs
also in AD patients.
These data show that cutaneous S. aureus is sufficient to
induce MDSCs and to cause immune suppression.mmunity 41, 762–775, November 20, 2014 ª2014 Elsevier Inc. 763
Figure 1. Cutaneous Staphylococcus aureus Induces Immune Suppression in Mice and Humans
(A–E) FITC-sensitized WT mice were treated following the protocol in Figure S1A (with living WT or lipoprotein mutant (Dlgt) S. aureus). Bacterial load as colony-
forming units (cfu) (mean ± SD, n = 5) (A), ear swelling (mean ± SD, n = 5) (B), histology (H&E staining) (C), proliferation of skin-draining lymph node (LN) cells
stimulated ex vivo with FITC (detected as counts per minute [cpm] of 3H-thymidine incorporation) (mean ± SD of triplicates) (D), and the percentage of cell
populations in the spleen (mean ± SD, n = 5) (E) were investigated. *p < 0.05.
(F) PBMCs from atopic dermatitis (AD) patients (n = 33) and healthy volunteers (n = 30) were analyzed forMDSCs, defined asCD11b+CD33+HLA-DRCD14 cells.
The dots represent individual values, and the horizontal bar is the groupmean. Red squares representMDSCsof patientswith severe AD and eczema herpeticum.
*p < 0.05 (Mann-Whitney test). Data are representative of at least two independent experiments. See also Figure S1.
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Ligands Ameliorates T Cell-Mediated Recall Responses
Next, we investigated the intriguing finding that lipoprotein-defi-
cientS. aureus failed to induce immune suppression in our model
(Figure 1B). As lipoproteins are sensed by different TLR2 hetero-
dimers (Henneke et al., 2008), we have taken advantage ofmicro-
bial-derived molecules, which are exclusively bound by one
specific TLR2 heterodimer. We selected three lipopeptides for
our studies: TLR2-6 ligands diacyl lipopeptides FSL-1 and
Pam2Cys and the triacylated lipopeptide Pam3Cys that is often
used as a reference compound for TLR2-1 activation. As in our
previous model, lipopeptides were applied to the skin during
re-exposure of FITC-sensitized mice to FITC (see protocol Fig-764 Immunity 41, 762–775, November 20, 2014 ª2014 Elsevier Inc.ure S1A). Similarly to the livingS. aureus, the cutaneous exposure
to TLR2-6 ligand FSL-1 almost completely abrogated consecu-
tive FITC-specific recall responses (Figures 2A and 2B), FITC-
specific ex vivo T cell proliferation (Figure 2C) and orchestrated
splenic reduction of CD4+ and CD8+ T cells together with
MDSC accumulation (Figure 2D). This result was confirmed
with another TLR2-6 ligand, Pam2Cys (Figures 2E–2H). In
contrast to Pam2Cys, the TLR2-TLR1 ligand Pam3Cys failed to
suppress FITC-specific dermatitis and T cell proliferation (Figures
2E–2G). Accordingly, no reduction of CD4+ and CD8+ T cells and
no induction of Gr1+CD11b+ cells could be detected (Figure 2H).
These data show that cutaneous exposure to bacterial TLR2-
TLR6 ligands is sufficient to cause immune suppression and that
Figure 2. Cutaneous Exposure to TLR2-6 but Not TLR2-1 Ligands Ameliorates T Cell-Mediated Recall Responses of the Skin
WT mice were treated following the protocol shown in Figure S1A. Mice were cutaneously exposed to FSL-1 in (A)–(D) and Pam2Cys or Pam3Cys in (E)–(H). Ear
swelling response (mean ± SD, n = 5) (A and E), histology (H&E staining) (B and F), proliferation of skin-draining LN cells stimulated ex vivo with FITC (mean ± SD
of triplicates) (C and G), and the percentage of cell populations in the spleen (mean ± SD, n = 5) (D and H) are shown. Data are representative of at least two
independent experiments. Experiments shown in (A) were performed with FSL-1 from two different providers. *p < 0.05.
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Skin Infection-Induced MDSCs Suppress T Cell Immunityactivation of TLR2-TLR6 heterodimers differs in regard to
functional consequences from activation of TLR2-TLR1
heterodimers.
Further, in order to control whether the presentation of the
antigen FITC is directly influenced by Pam2Cys exposure, we
analyzed the number of FITC positive DCs 14 hr after cutaneous
FITC application and Pam2Cys exposure. There were no differ-
ences in the numbers of FITC positive CD11c+MHC-II+ cells
and other dendritic cell populations (dDCs, LCs) in draining
lymph nodes (Figure S1G). Similarly, the analysis of other cell
populations at this early stage of the response revealed com-
parable numbers of T cells (CD4+, CD8+), activated T cells
(CD4+CD25+) and proliferating cells (Ki67+) (Figure S1H), IL-10
producing cells, and Treg cells (Figure S1I) in both mouse
groups. The treatment of mice with cyclophosphamide for Treg
cell depletion failed to reverse Pam2Cys-induced immune sup-
pression (Figures S1J–S1L), further indicating that Treg cells
are not involved in this type of immune suppression.
Skin-Infection-Induced Immune Suppression Is
Mediated by Gr1+CD11b+ Myeloid-Derived
Suppressor Cells
Next, as proof of concept that MDSCs are the responsible cells
for the observed immune suppression upon cutaneous
Pam2Cys exposure, we depleted Gr1+ cells. This depletion
caused an abrogation of immune suppression (Figure 3A, right).
Inversely, the adoptive transfer of MDSCs, isolated from mice
previously exposed to Pam2Cys, resulted in reduction of both
FITC-specific dermatitis and T cell proliferation (Figures 3B and
3C). To investigate whether human MDSCs in AD patients with
intense cutaneous exposure to lipoproteins were suppressive,
we depleted CD11b+ cells from PBMCs and analyzed prolifera-
tion of activated T cells. The CD11b+ population among PBMCs
consists of antigen-presenting cells and, in addition, contains
MDSCs in AD, but not healthy individuals. Consequently, in
seven of eight healthy volunteers, CD11b depletion resulted in
reduced T cell proliferation (Figure 3D, left). On the contrary,
this was only observed in one out of 7 AD patients (Figure 3D,
right). These results demonstrate thatMDSCs, which are present
among the CD11b+ population in AD patients, but not in healthy
individuals, are immunosuppressive. Indeed, T cell receptor
z-chain was significantly downregulated in AD patients (Fig-
ure 3E), which is known to be one of the major features of
MDSC-mediated T cell inhibition (Zea et al., 2005).
Taken together, these data revealed that skin-infection-
induced immune suppression is mediated by MDSCs.
Myeloid-Derived Suppressor Cells Are Recruited to the
Skin in Mice and Humans
Detecting MDSCs in human blood and mouse spleen following
cutaneous innate immune sensing indicates systemic MDSC
expansion. Therefore, we next monitored the kinetics of MDSC
induction in mice in (1) the bone marrow (BM), its primary source
(Figure 4A, left), and (2) one site of MDSC enrichment, the spleen
(Figure 4A, right) at different time points after cutaneous
Pam2Cys exposure. Starting on day 2, Gr1+CD11b+ cells in the
BM increased and peaked at day 7 with about 75%of cells being
Gr1+CD11b+. In the spleen, both CD4+ and CD8+ T cells were
strongly reduced. Gr1+CD11b+ cells increased starting at day 4766 Immunity 41, 762–775, November 20, 2014 ª2014 Elsevier Inc.with up to 7-fold induction on day 11 following cutaneous
Pam2Cys exposure (Figure 4A).
In FITC-CHS, T cells migrate to the skin and elicit dermatitis.
Therefore, we analyzed whether MDSCs were also recruited to
the skin. Indeed, 8 hr after FITC challenge Gr1+CD11b+ cells
were significantly increased in the skin of mice previously
exposed to Pam2Cys (Figure 4B). Similarly, we compared
healthy skin with lesional skin from AD patients colonized or in-
fected with S. aureus. Flow cytometry analysis confirmed a sig-
nificant increase of MDSCs in the skin of AD patients compared
to healthy skin (Figure 4C), indicating that presence of bacteria
and subsequent skin inflammation induce MDSC accumulation
in the skin also in humans.
Suppression of T Cell Activation byMDSCs Is Induced by
Cutaneous Innate Immune Sensing
Recruitment of MDSCs to the skin suggested MDSC-mediated
suppression of T cell activation in the skin in vivo. As first indica-
tion, we found that the depletion of CD11b+ cells of isolated
skin cells caused a stronger T cell proliferation following stimula-
tion with anti-CD3-CD28 in comparison to cells not depleted of
CD11b+ cells (Figure S2A), confirming a suppressive function of
skin MDSCs ex vivo. Moreover, flow cytometry analysis of ear
skin tissue following the FITC challenge revealed a significant
decrease of CD3+ T cells (Figure 5A, right) and IFN-g production
(Figure 5A, left) in previously Pam2Cys-exposed mice. Expres-
sion analysis of other cytokines revealed a significant decrease
of the Th2 cell cytokine IL-4 (a target for a systemic AD treatment
[Beck et al., 2014]), IL-10, and a tendency for IL-17 inhibition (Fig-
ure 5B). The investigation of cutaneous chemokines in the skin
showed a downregulation of most analyzed chemokines (CCL2,
CCL3, CCL4, CCL5, CCL11, CCL13, CCL17, CCL20, CCL27).
Only T cell attracting CCL22 (a CCR4 ligand) and CCL28 (CCR3
and CCR10 ligand) were significantly upregulated (Figure 5C).
The corresponding chemokine receptors were expressed on
theMDSCs in theskin,blood,andbonemarrow (Figure5D),which
further indicates that MDSCs are attracted to the site (and by
similar mechanism) of T cell migration (Biedermann et al., 2002).
To explore the mechanisms mediating MDSC-induced im-
mune suppression, we isolated MDSCs 10 days after Pam2Cys
exposure. Flow cytometry analysis revealed the presence of
both Ly6C+ and Ly6G+ MDSCs. Morphological evaluation of iso-
lated MDSCs confirmed that Ly6G+ MDSC were granulocytic,
whereas Ly6C+ MDSCs were monocytic (Figure S2B). In the
skin, Gr1+CD11b+ cells were further characterized as CD11c-,
CD15-, MHC-II-, B220-negative and positive for CD16-32 and
partly positive for F4-80 (Figure S2C), and splenic Ly6C+ cells
had a similar phenotype (Figure S2C). Next, we isolated Gr-
1dimLy6GLy6C+CD11b+ (Ly6C+) and Gr-1hiLy-6G+CD11b+
(Ly6G+) MDSCs from Pam2Cys-exposed mice and cocultured
them with naive splenocytes (responder cells) activated with
anti-CD3-CD28 antibodies (Abs) at different ratios. Following
coculture with Ly6C+ MDSCs at a ratio of 2:1, almost complete
suppression of T cell proliferation was observed, while Ly6G+
cells were not suppressive (Figure 5E, left). Investigating the sup-
pressive activity more thoroughly revealed that Ly6C+ MDSCs
inhibited Th0 CD4+ T cells, as well as Th1-, Th2-, and Th17-
polarized cells (Figure S2D). MDSCs’ immunosuppressive activ-
ity is reported to be a result of the activation of inducible NOS
Figure 3. Myeloid-Derived Suppressor Cells Are Responsible for Skin-Infection-Induced Immune Suppression
(A) WT mice were treated with FITC with or without cutaneous Pam2Cys exposure following the protocol in Figure S1A. The mice were additionally treated with
Gr1 depleting (right) or with an isotype control antibody (left) at day 2 and 4. Ear swelling response (mean ± SD, n = 5, left) was evaluated. Data are representative
of two independent experiments.
(B and C) WT mice were treated following the protocol shown in Figure S1A (without Pam2Cys exposure). One group of mice received Ly6C-Ly6G positive cells
from donors that were sensitized with FITC and exposed to Pam2Cys. The control group received spleen cells from naive mice. The ear swelling response
(mean ± SD, n = 5) (B) and the FITC-specific proliferation of LN cells (as cpm, mean ± SD of triplicates) (C) were evaluated.
(D) CD11b+ cells of PBMCs from healthy volunteers (n = 8, left) and AD patients (n = 7, right) were depleted, and remaining PBMCswere stimulated with anti-CD3-
CD28-mAbs, and analyzed for proliferation. *p < 0.05 (Mann-Whitney test).
(E) PBMCs from healthy donors (n = 8) and AD patients (n = 7) were analyzed for TCR z-chain expression (mean fluorescence intensity [MFI], CD3+ gate of living
cells) by intracellular flow cytometry. Each dot represents an individual value, and the horizontal bar is the group’s mean. *p < 0.05 (Mann-Whitney test). See also
Figure S2.
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Skin Infection-Induced MDSCs Suppress T Cell Immunity(iNOS), leading to increased production of nitric oxide (NO) (Ga-
brilovich et al., 2001). Indeed, we found an increased iNOS
expression in the skin after FITC challenge in Pam2Cys-exposed
mice (Figure S2E), and Ly6C+ MDSCs from Pam2Cys-exposed
animals produced high concentration of NO (Figure 5E, middle).
NO production and T cell suppression by Ly6C+ MDSCs wasIcompletely abrogated in a transwell experiment (Figure 5E mid-
dle, Figure S2F), indicating thatMDSC activation is a prerequisite
for MDSC NO production and MDSC-mediated suppression.
Flow cytometry analysis of the coculture confirmed higher
expression of iNOS by Ly6C+ cells (with a very low expression
of arginase and IL-10 by both MDSC subsets) (Figure S2G). Inmmunity 41, 762–775, November 20, 2014 ª2014 Elsevier Inc. 767
Figure 4. Skin Infection-Induced MDSCs Accumulate in the Skin in Mice and Humans
(A) WTmice were treated following the protocol in Figure S1A. The percentage of CD4+, CD8+, or Gr1+CD11b+ cells in Pam2Cys-exposed mice were analyzed by
flow cytometry at indicated time points after Pam2Cys exposure in BM (left) and spleen (right) (mean ± SD, n = 3). Asterisks show significant differences compared
with t = 0 determined by one-way ANOVA followed by Dunnett’s post test. *p < 0.05. Data are representative of two independent experiments.
(B) Cells from ear skin, isolated 4 hr or 8 hr after FITC challenge, were analyzed by flow cytometry (gate: living cells). A representative flow cytometry plot (left),
means ± SD (n = 5) (middle), and total numbers of Gr1+CD11b+ cells (mean ± SD, n = 5) (right) are shown. Data are representative of three independent experiments.
(C) Cells isolated from skin samples of AD patients (n = 9) and non-AD-controls (n = 9) were analyzed by flow cytometry (gate: living cells) for MDSCs, defined as
CD11b+CD33+HLA-DRCD14 cells. A representative flow cytometry plot with the gating strategy first for CD11b+CD14 (top) and then CD33+HLA-DR
(bottom) and the percentage of the CD11b+CD33+HLA-DRCD14 cells (left) and cumulative analysis (right) are shown. Each of the dots represents an individual
value and the horizontal bar the group’s mean. *p < 0.05 (Mann-Whitney test). n.s., not significant.
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Skin Infection-Induced MDSCs Suppress T Cell Immunityaddition, the inhibition of iNOS by L-NMMA or L-NIL completely
abrogated MDSC-mediated suppression of T cell proliferation
(Figure 5E, right). Similarly, in PBMCs of AD patients we detected
a distinct iNOS+ population of CD11b+CD11c- cells. These cells
were completely absent in healthy individuals (Figure 5F). Impor-
tantly, we also detected iNOS+CD11b+CD11c cells in AD skin
(Figure 5G, Figure S2H).
All together, the above results indicate that skin-infection-
induced MDSCs are present in the skin in mice and humans,
where they inhibit T cell proliferation bymeans of cell-to-cell con-
tact and iNOS.
Pam2Cys-Induced Immune Suppression Is Dependent
on Cutaneous TLR2
Next, we investigated underlying mechanisms how innate im-
mune sensing in the skin initiates MDSCs. Therefore we deter-
mined the role of TLR2. Tlr2/ and WT mice were treated as
shown in Figure S1A with or without cutaneous Pam2Cys
exposure. In contrast to WT mice (Figure 6A, left), Tlr2/ mice
failed to inhibit FITC-specific CHS (Figure 6A right) and T cell
proliferation (Figure 6B), and no reduction of CD4+ and CD8+
T cell numbers and accumulation of MDSCs (Figure 6C) was
observed following Pam2Cys exposure. Cutaneous innate
immune sensing through TLR2 might act through skin resident
cells or recruited circulating blood immune cells. Thus, mouse
chimeras were generated to distinguish between TLR2 sensing
of skin resident or recruited hematopoietic cells, as depicted
in Figure S3A.Chimerismwas confirmedbyPCRofBMcells (Fig-
ure S3B). The percentage of MDSCs was analyzed following the
protocol shown in Figure S1A. WT mice, reconstituted with WT
BM cells (WT +WT-BM) andWTmice, reconstituted with Tlr2/
BM cells (WT + Tlr2/-BM), upregulated MDSCs following
Pam2Cys exposure (Figure 6D, top). In contrast, Tlr2/mice re-
constituted with WT BM (Tlr2/ + WT-BM) failed to accumulate
MDSCs, similar to control Tlr2/mice with Tlr2/BM (Tlr2/ +
Tlr2/-BM) (Figure 6D, bottom). Thus, TLR2 expression on
skin-resident cells, which next to keratinocytes includes radia-
tion-resistant skin-resident Langerhans or mast cells, is neces-
sary and sufficient for MDSC accumulation.
Next, we investigated a functional role of TLR2 on MDSCs.
Chimeric mice were generated by reconstitution with 50%
CD45.1 WT and 50% CD45.2-Tlr2/ BM (Figure S3C).
Following Pam2Cys exposure, approximately 20% of spleen
cells were MDSCs irrespective whether WT CD45.1 or Tlr2/
CD45.2 cells were analyzed (Figure S3D), demonstrating that
TLR2 is dispensable on MDSC precursor cells for MDSC induc-
tion and accumulation.
Cutaneous IL-6 Is Critically Required for MDSC
Induction
Our previous experiments showed that cutaneous Pam2Cys
sensing through TLR2 is sufficient to induce MDSCs and
consecutive suppression of cutaneous recall responses.
To identify underlying mechanisms, we first analyzed which
cells in the skin could be responsible for sensing Pam2Cys.
Immunofluorescence staining of TLRs after exposure of
mice to Pam2Cys or Pam3Cys showed an upregulation of
the corresponding TLR on keratinocytes (Figure 7A). Similar
analyses of human skin samples showed pronounced TLR2Iexpression in human skin albeit at lower amount in AD
compared to healthy skin (Figure S4A), as known from other
studies (Kuo et al., 2013). Next, we analyzed the functional
consequences of the TLR upregulation. We exposed mice
to different TLR ligands (Pam2Cys, Pam3Cys, CpG, and
LPS) and analyzed cutaneous mRNA expression of cutaneous
cytokines. All TLR ligands moderately upregulated Tnf and
the chemokine Cxcl2 was most dominantly induced by
Pam2Cys and Pam3Cys (Figure 7B). Upregulation of Il6
mRNA in the skin was most pronounced only after Pam2Cys
exposure. In comparison to skin following FITC-only or
FITC-plus-other TLR-ligands exposure, cutaneous Pam2Cys
exposure induced a 400-fold upregulation of Il6 mRNA (Fig-
ure 7B, right). On the protein level, we detected increased
IL-6 production by CD45 negative cells (which were also
MHC-II negative, Figure S4B) (Figure 7C). To confirm these
data, we stimulated primary human keratinocytes with TLR
ligands and detected upregulation of IL-6 production exclu-
sively following Pam2Cys treatment (Figure 7D).
To regulate MDSC induction in the bone marrow (Figure 4A),
cutaneous IL-6 needs to reach the bloodstream (Chalmin et al.,
2010). Indeed, IL-6 concentrations in mouse sera strongly
increased 1 day after cutaneous Pam2Cys exposure (Figure 7E).
These data suggest that IL-6 plays a crucial role in Pam2Cys-
induced MDSC induction; therefore, Il6/ mice were investi-
gated. In contrast to WT mice, cutaneous Pam2Cys exposure
in Il6/ mice failed to suppress FITC-CHS (Figure 7F), and
no induction of MDSCs could be detected (Figure 7G). Conse-
quently, the injection of IL-6 into the mice caused an increase
of MDSCs in the spleen (Figures S4C and S4D), suggesting
that IL-6 is responsible for MDSC induction and expansion.
To investigate whether IL-6 plays a role in MDSC migration to
the skin, we applied anti-IL-6 antibody shortly before challenge
and analyzed MDSC numbers in the skin. We found a sig-
nificant and unequivocal increase of Gr1+CD11b+ cells in
both conditions (Figure S4E), and the adoptive transfer of
MDSCs into Il6/ mice showed a suppression of immune re-
sponses, comparable to what is observed in WT mice (Fig-
ure S4F). To investigate whether IL-6 plays a role for MDSC
development, we analyzed MDSCs generation in vitro. BM-
derived MDSCs (see Supplemental Experimental Procedures)
were treated with IL-6 during development, and their suppres-
sive function was investigated in a suppression assay with
responder cells. As shown in Figure 7H, the exposure of
MDSCs to IL-6 during generation enhanced their suppressive
function. These data indicate that IL-6 supports induction and
development of suppressive MDSCs, but not their migration
to the skin.
Taken together, these data suggest a scenario in which
Pam2Cys is sensed by TLR2 on skin resident cells, leading to
the expression and secretion of IL-6 in such high amounts that
MDSCs expand and accumulate, leading to the inhibition of
cutaneous recall responses.
DISCUSSION
In this study, we found that cutaneous exposure to bacteria and
bacterial substances known to act as potent MAMPs induced a
strong immune suppression mediated by MDSCs. Thesemmunity 41, 762–775, November 20, 2014 ª2014 Elsevier Inc. 769
Figure 5. Skin Infection-Induced MDSCs Suppress T Cell Activation through Mechanisms Requiring NO Production
(A) WT mice were treated following the protocol in Figure S1A. 24 hr (A and B) or 8 hr (C and D) after FITC challenge ear tissue cells were analyzed. (A) Flow
cytometry for CD3+ cells (left) and IFN-g production (right). A cumulative result (means ± SD, n = 5) is shown.
(B andC) Quantitative RT-PCR analysis for cytokines (B) or chemokines (C) (normalized to housekeeping genesActb-Gapdh) andmeans ± SEM (n = 5) are shown.
Expression of the skin of FITC only-exposed mice was set as 1. *p < 0.05.
(D) Cells isolated from BM, blood, and skin of Pam2Cys-treated mice were analyzed for chemokine receptor expression by flow cytometry (gate: Gr1+CD11b+ of
living cells), shown as percentage of Gr1+CD11b+ (means ± SD, n = 5).
(E) Spleen cells were cocultured in vitro with Ly6C+ or Ly6G+ MDSCs as indicated, stimulated by anti-CD3-CD28-mAbs and analyzed for proliferation (left);
supernatants (ratio 2:1) were analyzed for NO production by Griess reaction (mean ± SD of experimental triplicates) (middle), and iNOS inhibitors L-NMMA and
(legend continued on next page)
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Skin Infection-Induced MDSCs Suppress T Cell Immunityfindings highlight that certain classes of bacterial molecules are
able to orchestrate unique pathways that, even after limited
cutaneous exposure, are sufficient to induce immune suppres-
sion. We found that cutaneous exposure to TLR2-TLR6 but not
to TLR2-TLR1 ligands induced MDSCs and consecutive cuta-
neous immune suppression. Bacteria differ in the acylation pat-
terns of their lipoproteins (Kurokawa et al., 2012b). Our results
suggest that they might differ in their potential to activate
different TLR2 heterodimers and to regulate immune responses
as well. Consequently, acylation properties might characterize
bacteria as pathogens or commensals. It was shown recently
that the degree of lipoprotein-acylation depends on environ-
mental factors and growth phase. Lipoprotein SitC was triacy-
lated when S. aureus was in the exponential growth phase at
neutral pH and diacylated in the postexponential phase at low
pH (Kurokawa et al., 2012a). At the situation on the skin, where
pH is low and chronic S. aureus colonization (which is almost
always found in AD) is present, a postexponential growth
phase of S. aureus can be assumed. Consequently, lipoproteins
from S. aureus on the skin are more diacylated. On the basis
of our data and also own recently published data (Kaesler
et al., 2014), we hypothesize that diacylation of lipoproteins
induces acute inflammation followed by immune suppression
as a consequence. Further, one can also assume that patho-
genic and nonpathogenic skin microflora might have different
acylation properties and therefore different compositions of
TLR2 ligands and thus overall differ in regard to their immune
consequences.
Previous data obtained using a systemic sepsis model with
Gram-negative bacteria derived from the gut described the
MyD88 and TLR4 pathway to be most relevant for MDSC
expansion (Delano et al., 2007). However, the exact cascade
of events was not investigated (Arora et al., 2010; Delano
et al., 2007). Our data investigating the common route of cuta-
neous infection with Gram-positive bacteria show that TLR2
activation on skin-resident cells mediates MDSC accumulation
and consecutive immune suppression. Induction of MDSCs by
activation of cutaneous TLR2-6 most dominantly involves IL-6.
Cutaneous innate immune cells (Blander and Medzhitov,
2004), keratinocytes, and even melanocytes (Stadnyk, 1994;
Takashima and Bergstresser, 1996) are all capable of producing
innate cytokines, such as IL-6. Indeed, in AD, where keratino-
cytes act as a critical first line of defense against microbes, early
IL-6 production has been described after direct contact of ker-
atinocytes with S. aureus (Sasaki et al., 2003). Moreover, IL-6
has been found to be increased in AD skin (Fedenko et al.,
2011) and especially in AD skin lesions (Travers et al., 2010),
in which the amount of IL-6 correlates with bacterial burden
(Travers et al., 2010). Genome-wide association studies recently
also identified an IL-6 receptor (IL-6R) variant as a risk factor for
AD (Esparza-Gordillo et al., 2013) and a small case series with
three patients has demonstrated therapeutic efficacy of an IL-L-NIL were added to the coculture (right). Significant differences between expe
post-hoc test (*p < 0.05). Data are representative of at least two independent ex
(F) PBMCs from healthy donors and AD patients were analyzed by intracellular fl
result out of seven individuals is shown.
(G) Skin tissue of AD patients was analyzed by immunofluorescence. Arrows in
represents 25 mm. See also Figure S2.
I6R blockade by tocilizumab, an IL-6R antibody (Navarini et al.,
2011). These observations confirm the importance of IL-6 pro-
duction by skin cells in response to microbes; however, the pre-
cise immune consequences of cutaneous IL-6 induction had not
been elucidated. Our data allow us to propose a model of how
the cutaneous innate immune network functions: diacylated lip-
opeptides activate TLR2-TLR6 on skin resident cells followed
by marked IL-6 production leading to the MDSC accumulation,
which is a prerequisite of subsequent immune suppression by
MDSCs. Our data also indicate that these TLR2-6-induced
MDSCs are prototypic MDSCs as characterized in other set-
tings. Moreover, our data have further identified that skin-infec-
tion-induced MDSCs suppressed immune responses in mice
and humans.
In conclusion, our study reveals a consequence of cutaneous
innate immune sensing for adaptive immune functions. The pres-
ence of certain lipoproteins on the skin might serve not only as
danger signal for the initiation of effective immune responses
but also might be able to counterregulate inflammation and
potently control and suppress immune responses.
EXPERIMENTAL PROCEDURES
Animals
Specific-pathogen-free, WT BALB/cmice were purchased fromCharles River.
Tlr2/ mice (C57BL/6) were from C. Kirschning (Institute of Medical Microbi-
ology, University Duisburg-Essen) and were backcrossed to BALB/c for ten
generations. Il6/-BALB/c mice were from Dr. M. Kopf (Swiss Federal Insti-
tute of Technology). All mice were kept under specific pathogen-free condi-
tions in accordance with FELASA (Federation of European Laboratory Science
Association) in the University of Tu¨bingen. The experiments were performed
with the approval of the local authorities (Regierungspra¨sidium Tu¨bingen
HT1/10, HT3/11, HT7/11, HT5/13, HT8/13). Age-matched female mice were
used in all experiments.
Epicutaneous Mouse Skin Infection Model
The experimental model is based on epicutaneous application of the S. aureus
on shaved skin of mice (Wanke et al., 2013). Mice were sensitized with FITC
following the protocol as shown in Figure S1A. At days 7 and 10 3 3 108 WT
or lgt mutant S. aureus Newman in 30 ml PBS or PBS control were added to
filter paper discs placed onto the prepared skin and covered by Finn Cham-
bers on Scanpor (Smart Practice). Before application to the skin, barrier was
disrupted by tape stripping.
FITC Contact Hypersensitivity and Exposure to TLR2 Ligands
Mice were sensitized by administration of 80 ml of a 0.37% FITC solution
(dissolved in 1:1 acetone:dibutyl phthalate, Sigma Aldrich) on the shaved
abdomen on days 8 and 7. TLR2 ligands were applied intracutaneously
together with the second epicutaneous application of FITC on days 1 and
0 (Figure S1A) in the following concentrations per mouse: Pam2Cys, 2 mg;
Pam3Cys, 4 mg; FSL-1, 40 mg. Control mice obtained PBS instead of TLR2
ligands. At day 7, mice were challenged by epicutaneous application of
0.37%FITCsolutiononboth sidesof theears.Ear thicknesswasmeasuredwith
a micrometer (Oditest) as previously described (Volz et al., 2014), and data are
expressed as change in ear thickness compared to thickness before treatment.
In some experiments, mice were treated with 0.3 mM CpG 1668 (0.2 mM,rimental conditions were assessed by one-way ANOVA followed by Tukey’s
periments.
ow cytometry (iNOS+ in CD11b+CD11c Gate of living cells). A representative
dicate cells positive for CD11b and iNOS and negative for CD11c. Scale bar
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Figure 6. Pam2Cys-Induced Immune Suppression Is Dependent on TLR2
(A–C) WT and Tlr2/mice were treated following the protocol shown in Figure S1A and ear swelling (mean ± SD, n = 5) after FITC challenge (A), proliferation of
lymph node cells after FITC stimulation ex vivo (mean ± SD of triplicates) (B), and the percentage of spleen cell populations (mean ± SD, n = 5) (C) were analyzed.
(D)WT or Tlr2/mice were irradiated and reconstitutedwithWT or Tlr2/BMcells (see Figure S3A). Seven weeks later, the chimericmicewere treated following
the protocol shown in Figure S1A and their spleen cells were analyzed by flow cytometry. The percentage of Gr1+CD11b+ cells is shown (mean ± SD, n = 5). Data
are representative of three independent experiments. *p < 0.05, n.s., not significant. See also Figure S3.
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Skin Infection-Induced MDSCs Suppress T Cell ImmunityEurofinsGenomics), 1 mg/mouseLPS (fromSalmonellaminnesotaR595, Alexis
Biochemicals), cyclophoshamide (2 mg/mouse, Sigma-Aldrich), 20 mg/mouse
rmIL-6 (20 mg/mouse) or 50 mg/mouse anti-IL-6 (BioLegend).772 Immunity 41, 762–775, November 20, 2014 ª2014 Elsevier Inc.Human MDSCs
The study was approved by the local ethics committee of the University of Tu¨-
bingen, Germany, and written informed consent was obtained from all
Figure 7. IL-6 Is Required for Induction of Gr1+CD11b+ Cells and Pam2Cys-Induced Immune Suppression
(A–C) WT mice were treated following a protocol similar to that shown in Figure S1A. 24 hr after cutaneous exposure to TLR ligands or PBS (control), immu-
nofluorescence for TLR2 (red), TLR6 or TLR1 (blue), and nuclei (green) was done in (A), a representative picture (n = 3) is shown. Scale bar represents 30 mm (B).
The skin was evaluated for the expression of Tnf, Cxcl2, and Il6mRNA by quantitative RT-PCR analysis (normalized to housekeeping gene Actb). Expression in
the skin of untreated mice (naive) was set as 1 (mean ± SD, n = 5). (C) Skin cells were isolated and analyzed for IL-6 production by intracellular flow cytometry, and
a cumulative analysis (mean ± SD, n = 5) is shown.
(D) Primary human keratinocytes were isolated and treated with TLR ligands for 24 hr, and the production of IL-6 was measured by ELISA (mean ± SD of trip-
licates).
(legend continued on next page)
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Skin Infection-Induced MDSCs Suppress T Cell Immunitysubjects (project number 344/2011BO2, 345/2011BO2, 396/2011BO2, 040/
2013BO2, 180/2013BO2). PBMCs were obtained from heparinized blood by
centrifugation (800 g for 30 min) using Ficoll-Histopaque (Biochrom). MDSCs
in the blood or skin of either healthy volunteers or non-AD-controls or atopic
dermatitis patients were analyzed by flow cytometry and characterized as
CD11b+CD33+HLA-DRCD14 cells.
Bone-Marrow Chimeras
Recipient mice were lethally irradiated at 7.0 cGy and on the next day BM cells
(106 cells per recipient) were intravenously injected into recipient mice. To
confirm the chimerism of mice, we conducted genotyping of BM cells by
PCR for the WT and the mutated Tlr2 gene (Figure S3B).
Depletion of CD11b+ Cells
CD11b+ cells were depleted from PBMCs using the CD11b+ Beads (Miltenyi
Biotech) according to the manufacturer’s protocol.
Statistical Analysis
Unless otherwise stated, quantitative results are expressed as means ± SD
and differences were compared by unpaired, two-tailed Student’s t test (p <
0.05 was regarded as significant).
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